These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27161683)

  • 1. OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism.
    Young A; Phillips J; Hancocks H; Hill C; Joshi N; Marshall A; Grumett J; Dunn JA; Lokare A; Chapman O
    Thromb Res; 2016 Apr; 140 Suppl 1():S172-3. PubMed ID: 27161683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
    Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
    J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m).
    Marshall A; Levine M; Hill C; Hale D; Thirlwall J; Wilkie V; French K; Kakkar A; Lokare A; Maraveyas A; Chapman O; Arif A; Petrou S; Maredza M; Hobbs R; Dunn JA; Young AM
    J Thromb Haemost; 2020 Apr; 18(4):905-915. PubMed ID: 31995662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism.
    Jiménez D; Díaz G; Marín E; Vidal R; Sueiro A; Yusen RD
    Thromb Haemost; 2006 Mar; 95(3):562-6. PubMed ID: 16525588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin.
    Piatek CI; Tagawa ST; Wei-Tsai D; Hanna D; Weitz IC; O'Connell C; Rochanda L; Groshen S; Liebman HA
    Thromb Res; 2016 Apr; 140 Suppl 1():S174. PubMed ID: 27161687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE.
    Bach M; Bauersachs R
    Thromb Haemost; 2016 Sep; 116(Suppl. 2):S24-S32. PubMed ID: 27623682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B; Palareti G
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.
    Douketis JD; Foster GA; Crowther MA; Prins MH; Ginsberg JS
    Arch Intern Med; 2000 Dec 11-25; 160(22):3431-6. PubMed ID: 11112236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism.
    de Jong LA; van der Velden AWG; Hulst MV; Postma MJ
    BMJ Open; 2020 Nov; 10(11):e039057. PubMed ID: 33444193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
    Planquette B; Bertoletti L; Charles-Nelson A; Laporte S; Grange C; Mahé I; Pernod G; Elias A; Couturaud F; Falvo N; Sevestre MA; Ray V; Burnod A; Brebion N; Roy PM; Timar-David M; Aquilanti S; Constans J; Bura-Rivière A; Brisot D; Chatellier G; Sanchez O; Meyer G; Girard P; Mismetti P;
    Chest; 2022 Mar; 161(3):781-790. PubMed ID: 34627853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
    Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
    Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2).
    Davies GA; Lazo-Langner A; Gandara E; Rodger M; Tagalakis V; Louzada M; Corpuz R; Kovacs MJ
    Thromb Res; 2018 Feb; 162():88-92. PubMed ID: 28416213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
    Weitz JI; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Holberg G; Kakkar A; Lensing AW; Prins M; Haskell L; van Bellen B; Verhamme P; Wells PS; Prandoni P;
    Thromb Haemost; 2015 Aug; 114(3):645-50. PubMed ID: 25994838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.